Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, review timing and choice of first-line antiretroviral therapy in this unique program with a didactic video module and several case-based vignettes in which you are invited to help manage the patient.
Upon completion of this activity, participants should be able to:
HIV/AIDS Update From Boston 2014
NRTI-Sparing Regimens: The Search Goes On
D:A:D: Current Abacavir Use Remains Associated With Increased Risk of MI in HIV-Infected Patients
PHOTON-1: Sofosbuvir Plus RBV for 12 or 24 Weeks Results in High SVR12, SVR24 Rates in Patients Coinfected With HIV and HCV Genotypes 1, 2, or 3
PEARL-III: ABT-450/Ritonavir/ABT-267 + ABT-333 ± RBV for 12 Weeks Results in SVR12 Rates ≥ 99% in Treatment-Naive Patients With Genotype 1b HCV Monoinfection
Clinical Care Options, LLC. All Rights Reserved.